XXXX : two decades experience at Mayo clinic.

@entity1 @entity397 @entity439 @entity5475 @entity438
Although rare, splenic @entity438 (SAAs) have a definite risk of @entity397 . The optimal management of these @entity439 remains elusive. A retrospective chart review of all @entity1 treated at our institutions with the diagnosis of @entity5475 from January 1980 until December 1998 was undertaken. Follow-up was obtained via chart review and by direct phone contact of the @entity1 or relative. No specific protocol was followed for management. From analysis of the @entity1 data we concluded that although SAAs may @entity397 , not all intact @entity439 need intervention. Calcification does not appear to protect against @entity397 , although beta-blockade may be protective. Growth rates of @entity5475 are slow and growth is infrequent. Selective management of SAAs is safe. Open ligation or transcatheter embolization should be considered for symptomatic @entity439 , for @entity439 > or = 2 cm in size, or for any @entity5475 in @entity1 of childbearing years.
